Hirai Fumihito, Matsumoto Takayuki, Imai Keita, Goda Yuki, Fujimitsu Yuki, Kajioka Toshifumi, Oiwa Masami, Honjo Tomoki, Higashikawa Masaaki, Ueno Masato
Department of Gastroenterology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Iwate, Japan.
Crohns Colitis 360. 2025 Apr 9;7(2):otaf014. doi: 10.1093/crocol/otaf014. eCollection 2025 Apr.
BACKGROUND/AIMS: With the recent increase in available treatment options for inflammatory bowel disease (IBD), shared decision-making has gained considerable importance. To address potential disparities in patient and physician priorities, we conducted a survey to clarify these perspectives.
Patients with IBD and physicians treating IBD were asked to complete an online questionnaire focused on key factors influencing drug selection and preferred drug administration methods.
Responses were obtained from 400 patients (327 with ulcerative colitis and 73 with Crohn's disease) and 155 physicians. Among the factors in drug selection, physicians assigned significantly higher importance scores for experience with the drug than did patients. The expected time to onset of drug effects was significantly different between patients and physicians. Regarding preferences for drug administration method, patients and physicians assigned the highest acceptability scores for once-daily oral administration. For intravenous and subcutaneous routes, patients' scores were significantly lower than those of physicians' scores. Notably, 86.0% of patients and 62.0% of physicians preferred oral administration as the most preferred method. However, preferences varied based on treatment experience: 34.7% of patients with prior experience with subcutaneous injection preferred this method.
Patients and physicians generally shared similar priorities for drug selection; however, physicians emphasized their experience with the drug over patient preferences. Although the number of patients with prior treatment experience preferred intravenous or subcutaneous injections, oral formulations remained the preferred choice for both patients and physicians.
背景/目的：随着炎症性肠病（IBD）现有治疗选择的近期增加，共同决策变得相当重要。为了解决患者和医生优先事项方面的潜在差异，我们进行了一项调查以阐明这些观点。
IBD患者和治疗IBD的医生被要求完成一份在线问卷，重点关注影响药物选择的关键因素和首选给药方法。
共获得400名患者（327例溃疡性结肠炎患者和73例克罗恩病患者）和155名医生的回复。在药物选择因素中，医生对药物经验给予的重要性评分显著高于患者。患者和医生对药物起效预期时间存在显著差异。关于给药方法偏好，患者和医生对每日一次口服给药的可接受性评分最高。对于静脉和皮下途径，患者的评分显著低于医生的评分。值得注意的是，86.0%的患者和62.0%的医生更倾向于口服给药作为最优选方法。然而，偏好因治疗经验而异：34.7%有皮下注射既往经验的患者更喜欢这种方法。
患者和医生在药物选择上总体上有相似的优先事项；然而，医生更强调他们对药物的经验而非患者偏好。尽管有既往治疗经验的患者中有一部分更喜欢静脉或皮下注射，但口服制剂仍是患者和医生的首选。
